HIGH-RISK MULTIPLE MYELOMA: TREATMENT
OPTIONS IN CHINESE CENTRES
Prepared by the CancerFax oncology navigation team. Updated regularly based on treatment access and clinical availability.
analyticsAt a Glance
- check_circleHigh-risk myeloma is defined by del(17p), t(4;14), t(14;16), and other cytogenetic factors
- check_circleCAR-T therapy (BCMA, GPRC5D) offers responses in high-risk patients who fail standard regimens
- check_circlePeking University Cancer Hospital and Shanghai Changzheng Hospital lead China's myeloma programmes
- check_circleCancerFax coordinates eligibility review and referral to specialist myeloma centres in China
What βHigh-Riskβ Means in Multiple Myeloma
Multiple myeloma is not one disease. Patients with the same diagnosis can follow very different paths depending on the biology of the disease, how it presents, and how it responds to treatment. Over the last decade, large cooperative groups have refined risk classification using a combination of genetics, staging, and clinical behaviour. Risk classification matters because it influences how aggressively the disease should be treated upfront, how long maintenance should continue, and how early advanced therapies such as CAR T-cell treatment should be considered. Two staging systems are most relevant. The Revised International Staging System (R-ISS) combines ISS stage, LDH, and high-risk FISH cytogenetics. The newer R2-ISS adds 1q gain or amplification, which is now recognised as an independent adverse feature. The features that most often place a patient in the high-risk group are summarised below. Risk is not destiny. Many high-risk patients still achieve deep, durable responses with modern therapy. The point of risk classification is not to predict the future for an individual patient, but to inform how intensively the disease should be treated and how closely it should be watched.
Why China Is Considered for High-Risk Multiple Myeloma
Families look at China for high-risk myeloma for several reasons. The major hematology centres in Beijing, Tianjin, Shanghai, Hangzhou, Suzhou, and other cities perform large volumes of myeloma transplants and have well-organised supportive care infrastructure. China is also one of the leading global centres for BCMA-directed CAR T-cell therapy. Several BCMA CAR T products have been developed and tested in Chinese centres, and the country runs an active portfolio of trials in BCMA, GPRC5D, FcRH5, and dual-target CAR T platforms β many of which are particularly relevant for high-risk and heavily pre-treated disease. Cost is generally meaningfully lower than in North America, Western Europe, or Singapore for an equivalent transplant or commercial CAR T product, while the clinical standard for these procedures is broadly aligned with international guidelines. For patients whose disease has stopped responding to standard agents, access to trial-based options can also expand the realistic next step list, which is often narrower at home.
Treatment Options Used in Chinese Centres
Treatment for high-risk myeloma is rarely a single decision. It is a sequence: induction, consolidation, maintenance, and then careful planning at relapse. Chinese centres typically follow international guideline frameworks while also offering specific advantages in cellular therapy. The major options are summarised below; what fits an individual patient depends on the specific case. Frontline therapy for newly diagnosed high-risk patients Modern induction for high-risk transplant-eligible patients usually involves a quadruplet regimen β typically a CD38 monoclonal antibody (daratumumab or isatuximab) combined with a proteasome inhibitor (bortezomib or carfilzomib), an immunomodulatory drug (lenalidomide), and dexamethasone. Common examples include Dara-VRd, Isa-VRd, and Dara-KRd. The aim is to achieve a very deep response, ideally minimal residual disease (MRD)βnegative remission, before consolidation. After four to six cycles of induction, fit patients usually proceed to autologous stem cell transplant with high-dose melphalan. In selected high-risk patients, particularly those with double-hit or triple-hit cytogenetics, the team may discuss a tandem autologous transplant, where a second transplant is performed three to six months after the first. After transplant, maintenance is usually longer and more combination-based for high-risk disease β for example lenalidomide combined with bortezomib or with ixazomib β rather than single-agent lenalidomide alone. BCMA CAR T-cell therapy B-cell maturation antigen (BCMA) is expressed on almost all myeloma cells, which makes it an excellent target for CAR T-cell therapy. China has a particularly strong BCMA CAR T ecosystem: equecabtagene autoleucel (CT103A), ciltacabtagene autoleucel, and idecabtagene vicleucel are among the products that have been developed, trialled, or approved in this space, with the dual-binding-domain LCAR-B38M construct having been pioneered in Chinese centres before its global development. BCMA CAR T-cell therapy is most often used in relapsed or refractory myeloma after multiple prior lines, including patients who have already had transplant. Earlier-line use is being studied in trials. Responses are often deep and durable, including in heavily pre-treated patients. The main risks are cytokine release syndrome (CRS), neurotoxicity (ICANS), prolonged cytopenias, and infection during the recovery period. Eligibility depends on prior therapy, BCMA expression where measured, organ function, disease tempo, and trial-specific criteria. GPRC5D and dual-target CAR T trials For patients who have already received BCMA-directed therapy or who relapse after BCMA CAR T, China runs an active portfolio of trials targeting GPRC5D, FcRH5, and dual-target constructs such as BCMA-CD19 and BCMA-GPRC5D. These options are not standard of care; they are clinical trials, with all the eligibility, manufacturing, and access constraints that come with trial-based treatment. For some heavily pre-treated patients with otherwise limited options, these trials are nonetheless an important addition to the realistic next-step list. Allogeneic stem cell transplant Allogeneic transplant uses healthy donor stem cells and offers an immune-mediated effect against myeloma (graft-versus-myeloma). It is associated with significant risks, including graft-versus-host disease, infection, and treatment-related mortality, and is reserved for selected younger and fitter patients with very high-risk disease, often after relapse from autologous transplant. It is not a routine option for most high-risk patients and is considered case by case at experienced Chinese hematology centres. Other relapsed and refractory options Beyond cellular therapy, relapsed or refractory high-risk myeloma may be managed with new combination regimens that introduce drug classes the patient has not yet seen, selinexor-based combinations, belantamab mafodotin where available, and clinical trials of bispecific antibodies and other novel agents. Availability and access to these specific drugs differ between centres in China, and the treating team will tailor the plan based on prior exposure and current disease behaviour.
Who May Be Suitable
There is no single profile of a high-risk myeloma patient who fits a single treatment plan. Suitability for each option is assessed against: Patients who are not candidates for transplant or CAR T at this point in their journey are not without options. Continuous combination therapy, supportive care, and re-evaluation as new agents become available all remain part of the plan. The role of CancerFax is to help the family understand the realistic next step rather than push a single therapy.
Confirmed myeloma diagnosis with full FISH cytogenetics and
Confirmed myeloma diagnosis with full FISH cytogenetics and ISS or R-ISS staging
Response to induction therapy and depth of remission (very g
Response to induction therapy and depth of remission (very good partial response or better is generally preferred before transplant)
Cumulative prior therapy, including drug classes already use
Cumulative prior therapy, including drug classes already used and best response achieved with each
Disease tempo at the time of decision (slowly progressive vs
Disease tempo at the time of decision (slowly progressive vs rapidly progressive)
Age, performance status, and frailty assessment
Age, performance status, and frailty assessment
Cardiac, pulmonary, hepatic, and renal function β high-dose
Cardiac, pulmonary, hepatic, and renal function β high-dose melphalan and CAR T both place demands on these systems
Active infections, recent thrombotic events, or other comorb
Active infections, recent thrombotic events, or other comorbidities that affect intensive therapy
Adequate stem cell collection (for transplant) or adequate T
Adequate stem cell collection (for transplant) or adequate T-cell counts (for CAR T)
Travel fitness and ability to remain in China for the planne
Travel fitness and ability to remain in China for the planned duration
Documents Usually Required for Review
A meaningful high-risk myeloma assessment depends on having a complete and current case file. The records most centres in China will want to see include: If reports are in a regional language, English translations help the review move faster. Where reports are missing, our team helps the family identify exactly what to ask the treating hospital for before submission.
Latest medical summary and diagnosis report
Latest medical summary and diagnosis report
Bone marrow aspirate and biopsy reports, including plasma ce
Bone marrow aspirate and biopsy reports, including plasma cell percentage and immunophenotyping (flow cytometry) where available
FISH cytogenetics and karyotype reports β specifically looki
FISH cytogenetics and karyotype reports β specifically looking for del(17p), t(4;14), t(14;16), t(14;20), 1q gain or amplification, and del(1p)
ISS or R-ISS staging summary, with albumin, beta-2 microglob
ISS or R-ISS staging summary, with albumin, beta-2 microglobulin, and LDH
Serum protein electrophoresis (SPEP), serum immunofixation,
Serum protein electrophoresis (SPEP), serum immunofixation, serum free light chains (kappa and lambda with ratio), and 24-hour urine studies
Quantitative immunoglobulins
Quantitative immunoglobulins
Full blood counts, liver and kidney function, and calcium
Full blood counts, liver and kidney function, and calcium
Imaging
whole-body low-dose CT, PET CT, or whole-body MRI to assess bone disease and any extramedullary involvement
Echocardiogram and pulmonary function tests where available
Echocardiogram and pulmonary function tests where available
Infection screening
hepatitis B, hepatitis C, HIV, syphilis, CMV, and tuberculosis status
Full record of all prior therapy with regimen, doses, dates,
Full record of all prior therapy with regimen, doses, dates, cycles, best response, and reason for switch
Records of any prior transplant, including conditioning used
Records of any prior transplant, including conditioning used and engraftment course
How CancerFax Helps
CancerFax supports families with high-risk myeloma through a structured pathway:
Case review and risk classification check. We review the dia
Case review and risk classification check. We review the diagnosis, FISH cytogenetics, staging, prior therapy, and current status to confirm whether the case truly meets high-risk criteria and what the realistic next-step options are.
Centre and trial matching. Records are shared with appropria
Centre and trial matching. Records are shared with appropriate hematology, transplant, and CAR T-cell therapy teams in China. Where commercial options are not the right fit, we help identify trial-based options that may add to the realistic list.
Treatment planning and cost clarity. Once a centre accepts t
Treatment planning and cost clarity. Once a centre accepts the case for management, the family receives a planning package covering the proposed sequence (induction adjustments, transplant, maintenance, or CAR T pathway), expected total stay, and a realistic cost range with assumptions clearly listed.
Visa, travel, and admission coordination. Medical visa invit
Visa, travel, and admission coordination. Medical visa invitation, accommodation suitable for an immunocompromised patient, interpreter support, and admission window are aligned so that arrival is smooth and the patient is not exposed to unnecessary delays.
On-ground support during treatment. From admission through d
On-ground support during treatment. From admission through discharge, we stay involved as a single point of contact for the family, translating medical updates, supporting communication when the plan changes, and helping the family understand what is happening during transplant or CAR T recovery.
Discharge and home-country follow-up. Before the family leav
Discharge and home-country follow-up. Before the family leaves, we help compile the treatment summary, conditioning or CAR T product details, recovery course, and recommended maintenance plan in a clean format the local hematologist can use to continue care.
Where This May Be Available in China
Several major centres in China have well-established high-risk myeloma programmes, often paired with active CAR T-cell therapy capability. Examples that families commonly ask about include: The most appropriate centre for a given high-risk patient depends on diagnosis, cytogenetic profile, prior treatment, urgency, and the family's practical situation. CancerFax helps families select a centre that fits the case rather than choosing by name alone.
Institute of Hematology and Blood Diseases Hospital, Chinese
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Tianjin) β a leading national hematology centre with deep myeloma experience
Peking University People's Hospital, Beijing β well-known fo
Peking University People's Hospital, Beijing β well-known for hematology, transplant, and cellular therapy
Ruijin Hospital, Shanghai β long-standing leukaemia and myel
Ruijin Hospital, Shanghai β long-standing leukaemia and myeloma programmes with active research
Changzheng Hospital, Shanghai β significant CAR T-cell thera
Changzheng Hospital, Shanghai β significant CAR T-cell therapy experience in myeloma
First Affiliated Hospital of Soochow University (Suzhou) β s
First Affiliated Hospital of Soochow University (Suzhou) β strong transplant and cell therapy services
First Affiliated Hospital of Zhejiang University, Hangzhou β
First Affiliated Hospital of Zhejiang University, Hangzhou β active hematology and trial portfolio
Shanghai GoBroad Cancer Institute and Royal Lee Cancer Hospi
Shanghai GoBroad Cancer Institute and Royal Lee Cancer Hospital network β experienced in transplant and BCMA CAR T-cell therapy
Other university and provincial cancer hospitals with transp
Other university and provincial cancer hospitals with transplant and cell therapy accreditation
Frequently Asked Questions
Answers to common questions from patients and families.
How is high-risk multiple myeloma defined?
High-risk myeloma is defined by a combination of cytogenetic abnormalities and clinical features. Cytogenetic high-risk includes del(17p), t(4;14), t(14;16), t(14;20), and 1q gain or amplification. Clinical high-risk features include ISS Stage III with elevated LDH, extramedullary disease, plasma cell leukemia, and early relapse within twelve to eighteen months of starting therapy or after autologous transplant. Most modern definitions, including R-ISS and R2-ISS staging, combine these features. Final classification depends on the full case review by the treating hematologist.
Does high-risk myeloma mean a worse outcome no matter what we do?
No. Risk classification informs intensity of treatment, not destiny. With modern quadruplet induction, transplant, prolonged combination maintenance, and access to BCMA CAR T-cell therapy at relapse, many high-risk patients achieve deep, durable responses. Outcomes are still on average shorter than for standard-risk disease, but individual responses vary widely. The point of identifying high-risk features is to plan more intensive therapy and watch the disease more carefully, not to give up on treatment.
Should every high-risk patient have a tandem transplant?
No. Tandem transplant is considered in selected high-risk patients, particularly those with double-hit or triple-hit cytogenetics or persistent measurable residual disease after the first transplant. It carries more cumulative toxicity than a single transplant and is not the default. The decision is case by case and depends on cytogenetic profile, response to the first transplant, age, fitness, and patient preference. CancerFax helps families understand whether tandem transplant is being recommended on solid grounds or whether a different consolidation strategy is more appropriate.
Is BCMA CAR T-cell therapy used in newly diagnosed high-risk patients?
Generally not as standard care, although earlier-line use is being studied in trials. In current practice, BCMA CAR T-cell therapy is most often used in relapsed or refractory myeloma after multiple prior lines, including patients who have already had transplant. For newly diagnosed high-risk patients, the standard pathway remains quadruplet induction, transplant where eligible, and combination maintenance, with CAR T-cell therapy planned as a strong relapse option. Families exploring earlier CAR T should ask specifically about trial eligibility.
What if my disease has already relapsed after BCMA CAR T-cell therapy?
Relapse after BCMA CAR T is a recognised challenge. Options at that point may include a second BCMA-targeted therapy with a different construct or platform, GPRC5D-targeted CAR T trials, dual-target CAR T trials (such as BCMA-CD19 or BCMA-GPRC5D), bispecific antibody therapy where available, or new combination regimens. China runs an active trial portfolio in this space, which is one of the practical reasons families consider it for heavily pre-treated disease. Specific eligibility depends on the trial and the patient's case.
How long would I need to stay in China for a high-risk myeloma treatment plan?
Stay duration depends on the chosen pathway. A focused second opinion with selected investigations can be planned over one to two weeks. A single autologous transplant generally requires six to ten weeks in country. Tandem transplant typically requires four to six months. BCMA CAR T-cell therapy programmes typically require eight to twelve weeks. Allogeneic transplant, where considered, is usually a longer commitment of three to six months or more. CancerFax shares a realistic time plan in writing before any travel commitment.
Can CancerFax guarantee acceptance into a CAR T trial?
No. Acceptance into any CAR T trial in China depends on the trial team's review of the case, available manufacturing slots, the patient's clinical condition at screening, and protocol-specific criteria. CancerFax prepares the case carefully and submits it through appropriate channels, but the medical and trial decision rests with the treating team. If a particular trial is not feasible, we help identify other realistic options, including commercial CAR T products and combination regimens.
What if a Chinese centre says the patient is not eligible for the planned treatment?
An honest βnot a candidate at this pointβ answer is more useful than admission for a treatment that is not safe or appropriate. If the centre declines a specific pathway, we help the family understand exactly why, what would need to change for the patient to become a candidate (for example, better disease control or stabilisation of an organ function issue), and what realistic alternatives exist now. Sometimes that means a different therapy in China, sometimes it means continuing care closer to home.
Reference Data
Structured reference data summarizing key information for this topic.
| High-risk feature | Why it matters |
|---|---|
| del(17p) / TP53 deletion | Loss of the TP53 tumour-suppressor gene. Strongly associated with shorter remissions and resistance to standard agents. Often considered ultra-high risk if biallelic (TP53 mutation plus deletion). |
| t(4;14) | IgH translocation involving FGFR3 and MMSET. Historically high-risk, although outcomes have improved with proteasome inhibitor-based therapy. |
| t(14;16) and t(14;20) | IgH translocations involving MAF or MAFB. Less common than t(4;14), but considered high-risk in most modern definitions. |
| 1q21 gain or amplification | Gain (3 copies) or amplification (β₯4 copies) of chromosome 1q21. Now widely recognised as adverse and incorporated into R2-ISS staging. |
| del(1p) | Loss of chromosome 1p32 region. Associated with poorer outcomes in several large series. |
| Double-hit and triple-hit myeloma | Two or three high-risk cytogenetic abnormalities co-existing. Considered ultra-high risk and often prompts the most intensive frontline strategy. |
| ISS Stage III with high LDH | Combination of advanced biochemical staging and elevated LDH. Reflects aggressive disease behaviour. |
| Extramedullary disease | Plasmacytomas outside the bone marrow, especially in soft tissue or organs. Associated with shorter remissions and may need different systemic strategies. |
| Plasma cell leukemia | Circulating plasma cells in significant numbers. Aggressive variant requiring intensive multi-agent therapy and earlier consideration of cellular treatments. |
| Functional high-risk (early relapse) | Relapse within twelve to eighteen months of starting therapy or after autologous transplant, even without classic high-risk genetics. Treated with similar urgency. |
Reference Data
Structured reference data summarizing key information for this topic.
| Treatment option | When typically used | Key considerations |
|---|---|---|
| Quadruplet induction (Dara-VRd / Isa-VRd / Dara-KRd) | Newly diagnosed transplant-eligible high-risk patients. | Aim is deep response, ideally MRD-negative, before transplant. Usually 4β6 cycles. |
| Autologous stem cell transplant | After successful induction in fit patients up to roughly 65β70 years. | High-dose melphalan with stem cell rescue. Not curative but prolongs remission. |
| Tandem autologous transplant | Selected double-hit / triple-hit cases or those with persistent disease. | Two transplants 3β6 months apart. More toxicity, considered case by case. |
| Combination maintenance | After transplant in high-risk patients. | Lenalidomide with bortezomib or ixazomib often preferred over single-agent lenalidomide. |
| BCMA CAR T-cell therapy | Relapsed / refractory disease, often after multiple prior lines. | Deep responses possible. Risks include CRS, ICANS, cytopenias, infections. |
| GPRC5D and dual-target CAR T (trial-based) | Post-BCMA therapy or BCMA-relapsed disease. | Trial access only. Eligibility, manufacturing, and slots vary by protocol. |
| Allogeneic transplant | Younger, very high-risk patients in selected situations. | Higher toxicity and treatment-related mortality. Case-by-case decision. |
| Novel combinations and trials | Throughout the disease course where standard options are exhausted. | Bispecifics, selinexor combinations, antibody-drug conjugates where available. |
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Need Help Understanding Your Options?
If you or a family member has high-risk multiple myeloma, CancerFax can help organise the medical records, review whether the proposed treatment plan is appropriate, and connect the case with experienced hematology and CAR T-cell therapy centres in China. If a different pathway is more suitable for your case, we will tell you that openly. The goal is to help your family take the next responsible s
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.